Dr Klein begins the panel discussion by asking participants to name one of their biggest challenges. Dr Newcomer responds that time and the fact that there are not enough PhDs are challenging. Ms Torda suggests that standardized data and data collection remains difficult. Dr Scanlon says it's the nimbleness of structuring data.
Dr Klein begins the panel discussion by asking participants to name one of their biggest challenges. Dr Newcomer responds that time and the fact that there are “not enough†PhDs are challenging. Ms Torda suggests that standardized data and data collection remains difficult. Dr Scanlon says it's the “nimbleness†of structuring data.
The 3 panelists relate their perspectives on other challenges with data management, including the fact that many hospitals and providers are reluctant to risk losing accreditation from the NCQA if they reveal “bad data.†Dr Newcomer argues that these gaps in care present opportunity to improve quality of care.
The panelists also discuss how health information technology, such as electronic health records, might address challenges providers face such as time.
“When you can combine that registry information with the claims data, it's powerful; a lot of questions can be answered. I think what would be nice to sort of further overlay on that is some information from patients,†Dr Scanlon succinctly adds. “Thinking about how to merge that in–and if that resides and where it resides is difficult, admittedly–but I think important to think about for the future.”
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Trastuzumab Deruxtecan Receives FDA Approval for HER2-Positive Solid Tumors
April 5th 2024FDA granted accelerated approval to trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic HER2-positive solid tumors who received prior systemic treatment and have no satisfactory alternative treatment options.
Read More